SCHEMBL3526355

SCHEMBL3526355

COC(=O)CCC#Cc1cc(Cl)c(Cl)cc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36
GABRQ Q9UN88 1/20 0.36
MAPT P10636 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524974 0.89 HDAC3 (0.37) L3MBTL1LMNAGABRPGABRDGABRA1
SCHEMBL3527600 0.83 MAPT (0.43) L3MBTL1GABRPGABRDGABRA1GABRB1
SCHEMBL3526404 0.81 ALDH1A1 (0.43) L3MBTL1LMNAGABRPGABRDGABRA1
SCHEMBL31487595 0.79 HSD17B10 (0.36) L3MBTL1LMNAGABRPGABRDGABRA1
SCHEMBL3524291 0.78 KDM4E (0.43) L3MBTL1LMNAGABRPGABRDGABRA1
SCHEMBL3520159 0.78 GABRP (0.37) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL3524025 0.77 CREBBP (0.40) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL16738478 0.77 PGK1 (0.40) L3MBTL1LMNAGABRPGABRDGABRA1
SCHEMBL3524738 0.77 ALDH1A1 (0.53) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL3528298 0.76 MAPT (0.47) L3MBTL1MAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP L3MBTL1 4230/4885LMNA 849/4885GABRP 3264/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG L3MBTL1 4531/4885LMNA 1980/4885GABRP 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.